Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 7/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30634956 | 1.00 | BDKRB2 (0.57) | BDKRB2OPRM1OPRD1F2ACE | |
| SCHEMBL31206203 | 0.87 | BDKRB2 (0.61) | BDKRB2OPRM1OPRD1F2 | |
| SCHEMBL29512231 | 0.84 | BDKRB2 (0.48) | BDKRB2OPRM1OPRD1 | |
| SCHEMBL31575705 | 0.84 | F2 (0.61) | BDKRB2OPRM1OPRD1F2 | |
| SCHEMBL30469506 | 0.83 | ACE (0.59) | OPRM1OPRD1F2ACE | |
| SCHEMBL29739248 | 0.83 | BDKRB2 (0.59) | BDKRB2OPRD1F2 | |
| SCHEMBL29373242 | 0.82 | OPRM1 (0.46) | BDKRB2OPRM1OPRD1F2 | |
| SCHEMBL30974525 | 0.81 | OPRM1 (0.55) | BDKRB2OPRM1OPRD1 | |
| SCHEMBL29816663 | 0.80 | F2 (0.48) | BDKRB2OPRM1OPRD1F2ACE | |
| SCHEMBL31289567 | 0.80 | BDKRB2 (0.59) | BDKRB2OPRM1OPRD1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252693-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | NOVARTIS PHARMACEUTICALS CORPORATION | 2024-08-01 | — | — | US | disclosed |
| EP-4323017-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | Novartis AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| CN-117083088-A | Folate receptor targeted radiotherapy agent and use thereof | 诺华股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| WO-2022219569-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | NOVARTIS AG (CH) | 2022-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252693-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | FOLR1, FOLR2, FOLH1 | BDKRB2 385/4885OPRM1 2623/4885OPRD1 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.